REQUEST A DEMO
Total
USD $0.00
Search more companies

Medochemie (Far East) Ltd (Vietnam)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Medochemie (Far East) Ltd Profile Updated: February 21, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

The subject focuses on manufacturing pharmaceutical products (such as CNS drugs, anti-infective, analgesics, cardiovascular drugs, endocrine drugs, anti-diabetics, respiratory/ anti-allergic drugs, dermatological drugs, gastrointestinal drugs, etc.). The raw materials for production are imported from China, Thailand, India, Singapore, Hong Kong, etc. Along with domestic market, the subject's products are exported to Cyprus (the parent company).

Headquarters
No. 40, VSIP II, Road No. 6, Vietnam-Singapore II Industrial Park, Binh Duong Urban-Service-Industry Complex Area, Hoa Phu Ward
Thu Dau Mot; South Eastern Vietnam; Postal Code: 75000

Contact Details: Purchase the Medochemie (Far East) Ltd report to view the information.

Basic Information
Total Employees:
Purchase the Medochemie (Far East) Ltd report to view the information.
Outstanding Shares:
Purchase the Medochemie (Far East) Ltd report to view the information.
Registered Capital:
Purchase the Medochemie (Far East) Ltd report to view the information.
Incorporation Date:
September 16, 2008
Key Executives
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Medochemie (Far East) Ltd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency VND. Absolute financial data is included in the purchased report.
Net sales revenue
16.77%
Total operating revenue
16.77%
Operating profit (EBIT)
25.68%
Net Profit (Loss) for the Period
11.45%
Total assets
41.21%
Total equity
31.3%
Operating Profit Margin (ROS)
1.17%
Net Profit Margin
-0.67%
Return on Equity (ROE)
-3.78%
Debt to Equity Ratio
15.11%
Quick Ratio
0.11%
Cash Ratio
0.04%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?